EAM
MRNA icon

Eagle Asset Management’s Moderna MRNA Stock Holding History

Eagle Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-328,179
Closed -$33.9M – 583
2023
Q3 		$33.9M Buy
328,179
+286
+0.1% +$31.9K 0.2% 140
2023
Q2 		$39.8M Buy
327,893
+174,284
+113% +$23.2M 0.22% 134
2023
Q1 		$23.6M Sell
153,609
-51
-0% -$8.41K 0.14% 153
2022
Q4 		$27.5M Buy
153,660
+407
+0.3% +$66.5K 0.17% 147
2022
Q3 		$18.1M Buy
153,253
+944
+0.6% +$143K 0.12% 178
2022
Q2 		$21.8M Buy
152,309
+3,230
+2% +$462K 0.14% 173
2022
Q1 		$25.7M Buy
149,079
+294
+0.2% +$49.5K 0.13% 176
2021
Q4 		$37.4M Buy
148,785
+929
+0.6% +$272K 0.16% 167
2021
Q3 		$56.9M Sell
147,856
-227,725
-61% -$84M 0.26% 143
2021
Q2 		$88.3M Sell
375,581
-483,231
-56% -$86.4M 0.38% 105
2021
Q1 		$114M Buy
858,812
+198,264
+30% +$28.7M 0.5% 68
2020
Q4 		$69M Sell
660,548
-54,306
-8% -$5.49M 0.39% 91
2020
Q3 		$50.4M Sell
714,854
-2,537
-0.4% -$177K 0.26% 143
2020
Q2 		$44.5M Buy
+717,391
New +$39.3M 0.25% 145

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eagle Asset Management's MRNA Position: Q4 2023 in Review

Eagle Asset Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 328,179 shares — an estimated $33.9M sold.

Eagle Asset Management first reported a position in MRNA in Q2 2020 and held it in 14 quarters. The position peaked at $114M in Q1 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Eagle Asset Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Eagle Asset Management sold 328,179 Moderna shares in Q4 2023, an estimated $33.9M.
  • Eagle Asset Management first reported a position in Moderna in Q2 2020 and held it in 14 quarters.
  • Eagle Asset Management's Moderna position peaked at $114M in Q1 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Eagle Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.